ASTER-GUARDIANS
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winner was announced by Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare and the award was presented by Professor Jamie Waterall, Deputy Chief Public Health Nurse for the Office of Health Improvement & Disparities at Govt. of UK alongside Ms. Sheila Sobrany – President of Royal College of Nursing; Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare; and Mr. TJ Wilson – Executive Director and Group Head – Governance & Corporate Affairs, Aster DM Healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005491/en/
Margaret Helen Shepherd from the UK - Winner of the Aster Guardians Global Nursing Award 2023 (Photo: AETOSWire)
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognise the selfless contribution of nurses to millions of patients worldwide, Aster Guardians Global Nursing Award 2023 received an overwhelming response from nurses worldwide with over 52,000 nurses from 202 countries, a 116% growth from the last edition which had received 24,000 applications.
The award ceremony also saw a special video message from Dr. Tedros Adhanom Ghebreyesus – Director General of World Health Organisation being played to congratulate all the finalists and thank Aster DM Healthcare for the initiative.
On winning the award, Nurse Margaret said, “I am deeply humbled and grateful to receive the prestigious Aster Guardians Global Nursing Award. As healthcare professionals, we are privileged to be able to make a positive impact on the lives of our patients, and I feel blessed to be part of such a rewarding profession. This award not only recognises my personal achievements but also highlights the importance of nursing as a critical component of healthcare. Thank you to all my colleagues, mentors, and patients who have supported me throughout my career.”
Margaret has been dedicated to improving diabetes care through better diagnosis. She is the leading nurse for monogenic diabetes in the UK and provides advice to clinicians across the world regarding the management of this condition. She set up a national network of genetic diabetes nurses in 2002 to increase awareness of this condition (which is initially misdiagnosed in 80% of cases, resulting in patients being treated with unnecessary insulin injections). She was one of 70 national NIHR70@70 Senior Nurse Research Leaders (driving innovation and new roles to increase research awareness and engagement within clinical care) and has received the prestigious Florence Nightingale Foundation Leadership Scholarship.
Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “We are honoured to announce Ms Margaret Helen Shepherd from the United Kingdom as the winner of this year's Aster Guardians Global Nursing Award. She has exemplified the highest standards of patient care and dedication that is inspirational, and it deserves global recognition. Each one of the top 10 finalists have done phenomenal work and the Grand Jury had a tough time assessing and selecting the final winner. We are privileged to offer Aster Guardians Global Nursing Award as a platform to share and honor the accomplishments of exceptional nurses from around the globe.”
Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare said, “Aster Guardians Global Nursing Award is a small yet significant expression of gratitude that aligns with this year's International Nurses Day theme, ‘Our Nurses. Our Future’. Nurses ensure that patients receive high-quality care and often go beyond their call of duty to ensure that the right care is provided. This often helps them develop into other areas like research, innovation, mentorship, education, digitization among others as the stories of this year’s finalists and the winner have showcased. We as individuals and organizations must ensure that they receive the recognition they deserve, and this is where initiatives like Aster Guardians Global Nursing Award come into play. As a group, we will continue to support and celebrate the tireless efforts of nurses and put forth their inspiring stories of excellence.”
The rest of the 9 finalists, Cathy Cribben-Pearse from UAE, Christine Mawia Sammy from Kenya, Gloria Ceballo from Panama, Jincy Jerry from Ireland, Lilian Yew Siew Mee from Singapore, Michael Joseph Dino from Philippines, Shanti Teresa Lakra from India, Teresa Fraga from Portugal, and Wilson Fungameza Gwessa from Tanzania were also awarded with a monetary prize.
These nurses were selected through a stringent review process run by Ernst & Young LLP, a panel of Screening-Jury and the Grand Jury.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 125 clinics, 496* pharmacies, 20 labs and 157 patient experience centers in seven countries, including India. We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
* Including 239 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom